Robert M. Straubinger, PhD

UB Distinguished Professor of Pharmaceutical Sciences
School of Pharmacy, University at Buffalo/State University of New York 

DR. ROBERT M. STRAUBINGER is UB Distinguished Professor of Pharmaceutical Sciences at the U/B School of Pharmacy and Pharmaceutical Sciences. 

He also holds the position of Adjunct Professor in the UB Department of Pharmacology and Toxicology,
and is Adjunct Professor of Oncology at the Roswell Park Comprehensive Cancer Center where he participates in the graduate programs in Cell Stress and Biophysical Oncology and Experimental Therapeutics. He was also Adjunct Professor on the Faculty of Science and Health at Dublin City University, Ireland. 

Dr. Straubinger received dual B.A. degrees in English and Anthropology from the University of Rochester, an interdisciplinary M.S. degree concentrating in Natural Sciences/pathophysiology from the Roswell Park division of the University at Buffalo/SUNY.

He earned the Ph.D. degree in Pharmacology from the University of California at San Francisco, under the late Demetrios Papahadjopoulos, PhD, a pioneer in the field of nanoparticle drug delivery. Dr. Straubinger was a postdoctoral fellow in the Cancer Research Institute and in the Cardiovascular Research Institute at the University of California, San Francisco.

Dr. Straubinger's research focuses on the broad area of drug carriers and drug delivery, with an emphasis on the mechanisms by which drug carriers alter the pharmacology of carrier-associated drugs. The research approaches include biophysical investigations of the pharmaceutical properties of drug:carrier complexes, pharmacokinetic and pharmacodynamic analysis to probe mechanisms behind the therapeutic effects of drug carriers. A growing new research direction is the application of comprehensive proteomic analysis based on liquid chromatography/mass spectrometry (LC/MS) to identify pharmacodynamic effect 'biomarkers' in cancers, and to investigate pharmacological interactions of combination chemotherapy regimens at a molecular level. Current research funding focuses on mechanisms by which drug-mediated interdiction of specific of tumor-stromal interactions can modulate tumor vascular permeability and antibody/drug carrier deposition in tumors. 

Dr. Straubinger also serves as director of the Pharmaceutical Sciences Instrumentation Facility, which has facilities in the Pharmacy Bldg. on the UB South Campus and the New York State Center of Excellence Bioinformatics & Life Sciences Downtown Campus. 

319 Pharmacy Bldg, UB South Campus
Telephone: (716) 645-2844
Fax: (716) 645-3693

UB Center of Excellence in Bioinformatics and Life Sciences
(716) 881-8995 

Click here to send me email.      Click here for my departmental web page.
Here is a list of UB Pharmaceutical Sciences Faculty. 

Click here if you’re interested in our ‘academic family tree’.
If you’re a former lab member and wish to be included, send me an email.


Follow this link to my curated NCBI bibliography.
This link runs an up-to-date search of our publications in the PubMed database.
The full pre-publication text of most of our recently published papers can be found HERE in PubMedCentral, where publications reporting work on federally-funded research are archived. 

Recent Publications


1.         Johnston MC; Nicoll JA; Redmond KM; Smyth P; Greene MK; McDaid WJ; Chan DKW; Crawford N; Stott KJ; Fox JP; Straubinger NL; Roche S; Clynes M; Straubinger RM; Longley DB; Scott CJ. DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. J Control Release 324: 610-9 (2020). DOI:

2.         Roche S; O’Neill F; Murphy J; Swan N; Meiller J; Conlon NT; Geoghegan J; Conlon K; McDermott R; Rahman R; Toomey S; Straubinger NL; Straubinger RM; O’Connor R; McVey G; Moriarty M; Clynes M. Establishment and characterisation by expression microarray of patient-derived xenograft panel of human pancreatic adenocarcinoma patients. Int. J. Mol. Sci. 21: Art. 962 (2020). DOI:

3.         Luo D; Carter KA; Molins EAG; Straubinger NL; Geng J; Shao S; Jusko WJ; Straubinger RM; Lovell JF. Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals. J Control Release 297: 39-47 (2019). DOI:

4.         Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 42: 184-9 (2019). DOI:

5.         McDaid WJ; Greene MK; Johnston MC; Pollheimer E; Smyth P; McLaughlin K; Van Schaeybroeck S; Straubinger RM; Longley DB; Scott CJ. Repurposing of cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. RCS Nanoscale 11: 20261-73 (2019). DOI:

6.         Niu J; Straubinger RM; Mager DE. Pharmacodynamic drug-drug interactions. Clin Pharmacol Ther 105: 1395-406 (2019). DOI:

7.         Roy Chaudhuri T; Straubinger RM. Nanoparticles for brain tumor delivery. In (RR Lonser, M Sarntinoranont and K Bankiewicz ed.), Nervous System Drug Delivery: Principles and Practice, Elsevier/Academic Press, London, UK, 2019, pp. 229-50.

8.         Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM. Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model. Mol Cancer Ther 18: 2074-84 (2019). DOI:

9.         Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA. Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and Nab-paclitaxel in preclinical models of pancreatic cancer Clin Cancer Res 24: 2873-85 (2018). DOI:

10.       Coleman O; Henry M; O'Neill F; Roche S; Swan N; Boyle L; Murphy J; Meiller J; Conlon NT; Geoghegan J; Conlon KC; Lynch V; Straubinger NL; Straubinger RM; McVey G; Moriarty M; Meleady P; Clynes M. A comparative quantitative LC-MS/MS profiling analysis of human pancreatic adenocarcinoma, adjacent-normal tissue, and patient-derived tumour xenografts. Proteomes 6: 45 (2018). DOI:

11.       Diep JK; Covelli J; Sharma R; Ruszaj DM; Kaye KS; Li J; Straubinger RM; Rao GG. Comparison of the composition and in vitro activity of polymyxin B products. Int J Antimicrob Agents 52: 365-71 (2018). DOI:

12.       Sun BC; Straubinger RM; Lovell JF. Current taxane formulations and emerging cabazitaxel delivery systems. Nano Res 11: 5193-218 (2018). DOI:

13.       Vaidya T; Straubinger RM; Ait-Oudhia S. Development and evaluation of novel tri-functional immunoliposomes for the treatment of HER2 positive breast cancer. Pharm Res 35: art. 95 (2018). DOI:

14.       Wang X; Niu J; Li J; Shen X; Shen S; Straubinger RM; Qu J. Temporal effects of combined birinapant and paclitaxel on pancreatic cancer cells investigated via large-scale, ion-current-based quantitative proteomics (IonStar). Mol Cell Proteomics 17: 655-71 (2018). DOI:

15.       Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ. Multi-scale network model supported by proteomics for analysis of combined gemcitabine and birinapant effects in pancreatic cancer cells. CPT Pharmacometrics Syst Pharmacol 7: 549-61 (2018). DOI:

16.       Zhu X; Shen X; Qu J; Straubinger RM; Jusko WJ. Proteomic analysis of combined gemcitabine and birinapant in pancreatic cancer cells. Front Pharmacol: Pharmacology of Anti-Cancer Drugs 9: Art. 84, 14 pp (2018). DOI:

17.       Zhu X; Trueman SA; Straubinger RM; Jusko WJ. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. J. Pharmacokinet. Pharmacodyn. (2018). DOI: